BCC Distinguished From FBP By Immunolabeling

Folliculocentric basaloid proliferation (FBP) can be distinguished from basal cell carcinoma (BCC) by immunolabeling with the matrilin-2 antibody, according to a study published in the Journal of Cutaneous Pathology.

The presence of FBP while excising a BCC can lead to excessive tissue removal, so researchers compared matrilin-2 expression in peritumoral cells of BCC and FBP since BCCs invade the stroma and FBPs do not.

Matrilin-2 expression was increased within the peritumoral stroma of 97.7% of BCCs and strongly expressed in 100% of infiltrative cases and 84% of nodular forms of BCC. No peritumoral matrilin-2 expression was found in the FBP cases.

“Our results suggest that immunolabeling with the matrilin-2 antibody may help distinguish basal cell carcinomas from folliculocentric basaloid proliferations,” concluded the study authors.

Reference
Wang Z, Lee J, Breen C, et al. Peritumoral matrilin-2 staining may be useful in distinguishing basal cell carcinoma from folliculocentric basaloid proliferation. J Cutan Pathol. 2022;10.1111/cup.14222. doi:10.1111/cup.14222